Compare Crispr Therapeutics AG (CRSP) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ralph Lauren Corp — how do they compare? Crispr Therapeutics AG trades at $53.77 (market cap $5.23B), while Ralph Lauren Corp trades at $391.7 (market cap $23.70B). The key difference: Ralph Lauren Corp is far larger — about 4.5× Crispr Therapeutics AG's market cap, and Ralph Lauren Corp pays a 0.94% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | RL | |
|---|---|---|
Market Cap | $5.23B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $414.25 |
52-Week Low | $44.34 | $285.35 |
Enterprise Value | $3.65B | $24.76B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Ralph Lauren (RL) trades at $406.89, up 2.87% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support near $396 and resistance at $413. Fundamentals are robust, with Q2 2026 EPS of $4.59 beating estimates, revenue growth to $7.08B in 2025, and high profitability margins. Analyst sentiment is overwhelmingly positive, with 66% recommending Buy and a consensus price target of $456.50.
The outlook remains favorable due to brand strength and margin expansion, but risks include economic sensitivity and high valuation multiples. Near-term catalysts hinge on Q3 2026 earnings due soon. The stock's proximity to its 52-week high suggests cautious entry points may be optimal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
